Race, Comorbidity & Long Term Prostate Cancer Outcomes

种族、合并症

• 批准号: 7315908
• 负责人: DAVID F. PENSON
• 金额: $ 56.36万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-01 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7315908
• 关键词: Ablation; Address; Affect; Aging; Agonist; Anxiety; Biochemical; Bone Density; Cancer Patient; Cancer Survivor; Cancer Survivorship; Cardiovascular Diseases; Cardiovascular system; Clinical; Cohort Studies; Comorbidity; Condition; Data; Data Reporting; Data Set; Diabetes Mellitus; Diagnosis; Disease; Disease Progression; Ethnic Origin; Event; Health; Healthcare; Hip Fractures; Hormones; Intervention; Knowledge; Life; Literature; Long-Term Effects; Longitudinal Studies; Malignant neoplasm of prostate; Methodology; Minority Groups; Morbidity - disease rate; Newly Diagnosed; Numbers; Outcome; Patient Outcomes Assessments; Patients; Patterns of Care; Pharmaceutical Preparations; Policy Maker; Population; Prostate Cancer Outcomes Study; Prostate-Specific Antigen; Quality of life; Race; Recurrence; Registries; Regrets; Reporting; Research Personnel; Resources; Second Primary Cancers; Skeletal system; Socioeconomic Status; base; cancer diagnosis; cancer recurrence; cancer therapy; cohort; design; experience; follow-up; functional status; health related quality of life; improved; low socioeconomic status; member; men; novel; prospective; racial and ethnic; socioeconomics; statistics; therapy design; tumor progression

DESCRIPTION (provided by applicant): The long-term effects (10 years or more) of prostate cancer and treatment on clinical and patient-reported outcomes are not well understood. Furthermore, as patients live longer after their diagnosis, they are developing co-morbid conditions, experiencing cancer recurrences or progression and receiving secondary cancer therapies, all of which can affect their health and quality of life. A better understanding of these clinical events and their effects is essential to designing interventions to improve quality of life and for informing newly-diagnosed patients. We propose to use an existing and unique resource to improve our understanding of prostate cancer survivorship: the Prostate Cancer Outcomes Study (PCOS). The PCOS is a population-based cohort of men with prostate cancer followed longitudinally since their diagnosis in 1994-5. The dataset includes clinical and sociodemographic data, information on treatment and health-related quality of life (HRQOL) outcomes. The proposed study has the following three aims: 1) To characterize long-term (10-15 year) clinical outcomes, including biochemical recurrence (prostate-specific antigen), clinical disease progression, use of secondary cancer therapies and the onset or worsening of co-morbid illnesses and/or skeletal related events in a population-based cohort of prostate cancer survivors. 2) To assess the associations between these clinical outcomes and long-term disease-specific and general HRQOL. 3) To assess the independent associations of race/ethnicity and socioeconomic status (SES) with long- term clinical and HRQOL outcomes. To achieve these aims, we will collect 14-year data on disease recurrence/progression, receipt of secondary therapy, co-morbidity (including skeletal related and cardiovascular events), medication use, functional status and HRQOL in the surviving members of the PCOS cohort. The current PCOS cohort includes 2,348 men with prostate cancer from 6 SEER registries who have been followed since diagnosis with patient- reported data collected at 6,12, 24 and 60 months. Descriptive statistics will be used to achieve the first aim. For the second and third aims, appropriate multivariable statistical methodology will be used. When completed, this study will be the longest population-based prospective follow-up of prostate cancer survivors yet reported in the literature and will provide important information for prostate cancer survivors, clinicians, researchers and healthcare policy makers. Specifically, it will help newly-diagnosed patients make more informed decisions regarding treatment and will help researchers design novel interventions to improve the quality of life of prostate cancer survivors.

描述（由申请人提供）：前列腺癌的长期影响（10年或更长时间）以及对临床和患者报告结果的治疗尚不清楚。此外，随着患者诊断后的寿命更长，他们正在发展合并症，经历癌症复发或进展并接受继发性癌症疗法，所有这些都会影响其健康和生活质量。更好地了解这些临床事件及其影响对于设计干预措施以改善生活质量并告知新诊断的患者至关重要。我们建议使用现有的独特资源来提高我们对前列腺癌幸存者的理解：前列腺癌成果研究（PCOS）。自1994 - 5年诊断以来，PCOS是一个基于人群的前列腺癌男性队列。该数据集包括临床和社会人口统计学数据，有关治疗和与健康相关的生活质量（HRQOL）结果的信息。拟议的研究具有以下三个目的：1）表征长期（10 - 15年）的临床结果，包括生化复发（前列腺特异性抗原），临床疾病进展，使用继发性癌症疗法以及在基于人群基于人口癌症中的共同疾病和/或骨骼相关的事件的次要癌症疗法或疾病的发作或损害。 2）评估这些临床结果与长期疾病特异性和一般HRQOL之间的关联。 3）评估种族/种族和社会经济地位（SES）的独立关联以及长期临床和HRQOL结果。为了实现这些目标，我们将收集有关疾病复发/进展，次级治疗，合并症（包括骨骼相关和心血管事件）的14年数据，药物使用，功能状态和HRQOL在PCOS同伴中幸存。当前的PCOS队列包括来自6个SEER注册机构的2,348名前列腺癌男性，这些人自诊断以来一直在诊断为6,12、24和60个月的患者报告的数据。描述性统计数据将用于实现第一个目标。对于第二和第三目的，将使用适当的多变量统计方法。完成后，这项研究将是最长的基于人群的前列腺癌幸存者的前瞻性随访，并将为前列腺癌幸存者，临床医生，研究人员和医疗保健政策制定者提供重要信息。具体而言，它将帮助新诊断的患者做出有关治疗的更明智的决定，并将帮助研究人员设计新颖的干预措施，以改善前列腺癌幸存者的生活质量。